Liang Jing-Yao, Xiong Qi-Ying, Liang Xiao-Dong, Deng Jie, Ye Rui-Xian, Liu Huan-Yan, Dong Liang-Jiao, Zhang Xi-Bao
Institute of Dermatology, Guangzhou Medical University, Guangzhou, China.
Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China.
Dermatol Ther. 2020 May;33(3):e13389. doi: 10.1111/dth.13389. Epub 2020 May 22.
Discoid lupus erythematosus (DLE) is a chronic autoimmune skin disease that usually causes disfiguring scarring, dyspigmentation, and atrophy. Despite a range of available topical and systemic therapies, the treatment of DLE remains a therapeutic challenge, especially in some refractory cases. Here, we reported three male patients with long-term chronic lesions of unilateral facial localized DLE, who failed to have their disease controlled with many previous topical/systemic treatments, showed rapid and well response to intralesional injections of betamethasone (2 mg/mL, 0.2 mL/site) monotherapy once every 2 weeks for two, two, and four times of treatment, respectively. Intralesional betamethasone may provide a safe and effective alternative in the management of refractory localized DLE skin lesions.
